239 related articles for article (PubMed ID: 16061711)
1. Phosphodiesterase type 5 and high altitude pulmonary hypertension.
Aldashev AA; Kojonazarov BK; Amatov TA; Sooronbaev TM; Mirrakhimov MM; Morrell NW; Wharton J; Wilkins MR
Thorax; 2005 Aug; 60(8):683-7. PubMed ID: 16061711
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension.
Bharani A; Mathew V; Sahu A; Lunia B
Indian Heart J; 2003; 55(1):55-9. PubMed ID: 12760589
[TBL] [Abstract][Full Text] [Related]
3. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.
Ghofrani HA; Voswinckel R; Reichenberger F; Olschewski H; Haredza P; Karadaş B; Schermuly RT; Weissmann N; Seeger W; Grimminger F
J Am Coll Cardiol; 2004 Oct; 44(7):1488-96. PubMed ID: 15464333
[TBL] [Abstract][Full Text] [Related]
4. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension.
Michelakis ED; Tymchak W; Noga M; Webster L; Wu XC; Lien D; Wang SH; Modry D; Archer SL
Circulation; 2003 Oct; 108(17):2066-9. PubMed ID: 14568893
[TBL] [Abstract][Full Text] [Related]
5. Sildenafil citrate therapy for pulmonary arterial hypertension.
Galiè N; Ghofrani HA; Torbicki A; Barst RJ; Rubin LJ; Badesch D; Fleming T; Parpia T; Burgess G; Branzi A; Grimminger F; Kurzyna M; Simonneau G;
N Engl J Med; 2005 Nov; 353(20):2148-57. PubMed ID: 16291984
[TBL] [Abstract][Full Text] [Related]
6. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells.
Wharton J; Strange JW; Møller GM; Growcott EJ; Ren X; Franklyn AP; Phillips SC; Wilkins MR
Am J Respir Crit Care Med; 2005 Jul; 172(1):105-13. PubMed ID: 15817798
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides.
Steiner MK; Preston IR; Klinger JR; Hill NS
Curr Opin Pharmacol; 2005 Jun; 5(3):245-50. PubMed ID: 15907910
[TBL] [Abstract][Full Text] [Related]
8. Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition.
Botha P; Parry G; Dark JH; Macgowan GA
J Heart Lung Transplant; 2009 Jul; 28(7):676-82. PubMed ID: 19560695
[TBL] [Abstract][Full Text] [Related]
9. Signaling molecules in overcirculation-induced pulmonary hypertension in piglets: effects of sildenafil therapy.
Rondelet B; Kerbaul F; Van Beneden R; Motte S; Fesler P; Hubloue I; Remmelink M; Brimioulle S; Salmon I; Ketelslegers JM; Naeije R
Circulation; 2004 Oct; 110(15):2220-5. PubMed ID: 15466636
[TBL] [Abstract][Full Text] [Related]
10. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension.
Singh TP; Rohit M; Grover A; Malhotra S; Vijayvergiya R
Am Heart J; 2006 Apr; 151(4):851.e1-5. PubMed ID: 16569546
[TBL] [Abstract][Full Text] [Related]
11. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.
Lewis GD; Shah R; Shahzad K; Camuso JM; Pappagianopoulos PP; Hung J; Tawakol A; Gerszten RE; Systrom DM; Bloch KD; Semigran MJ
Circulation; 2007 Oct; 116(14):1555-62. PubMed ID: 17785618
[TBL] [Abstract][Full Text] [Related]
12. Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling.
Schäfer S; Ellinghaus P; Janssen W; Kramer F; Lustig K; Milting H; Kast R; Klein M
Cardiovasc Res; 2009 Apr; 82(1):30-9. PubMed ID: 19131365
[TBL] [Abstract][Full Text] [Related]
13. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure.
Guazzi M; Tumminello G; Di Marco F; Fiorentini C; Guazzi MD
J Am Coll Cardiol; 2004 Dec; 44(12):2339-48. PubMed ID: 15607396
[TBL] [Abstract][Full Text] [Related]
14. Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship.
Garg N; Sharma MK; Sinha N
Int J Cardiol; 2007 Sep; 120(3):306-13. PubMed ID: 17174417
[TBL] [Abstract][Full Text] [Related]
15. Low-dose phosphodiesterase inhibition improves responsiveness to inhaled nitric oxide in isolated lungs from endotoxemic rats.
Klein A; Zils U; Bopp C; Gries A; Martin E; Gust R
J Surg Res; 2007 Apr; 138(2):224-30. PubMed ID: 17275845
[TBL] [Abstract][Full Text] [Related]
16. Sildenafil therapy in secondary pulmonary hypertension: Is there benefit in prolonged use?
Chapman TH; Wilde M; Sheth A; Madden BP
Vascul Pharmacol; 2009; 51(2-3):90-5. PubMed ID: 19386283
[TBL] [Abstract][Full Text] [Related]
17. Effects of phosphodiesterase 5 inhibitor on pulmonary vascular reactivity in the fetal lamb.
Jaillard S; Larrue B; Deruelle P; Delelis A; Rakza T; Butrous G; Storme L
Ann Thorac Surg; 2006 Mar; 81(3):935-42. PubMed ID: 16488698
[TBL] [Abstract][Full Text] [Related]
18. Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy.
Kukreja RC; Ockaili R; Salloum F; Yin C; Hawkins J; Das A; Xi L
J Mol Cell Cardiol; 2004 Feb; 36(2):165-73. PubMed ID: 14871543
[TBL] [Abstract][Full Text] [Related]
19. Combined use of PDE5 inhibitors and nitrates in the treatment of pulmonary arterial hypertension in patients with heart failure.
Stehlik J; Movsesian MA
J Card Fail; 2009 Feb; 15(1):31-4. PubMed ID: 19181291
[TBL] [Abstract][Full Text] [Related]
20. A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease.
Madden BP; Allenby M; Loke TK; Sheth A
Vascul Pharmacol; 2006 May; 44(5):372-6. PubMed ID: 16574495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
